A5016014384- Computational Drug Discovery Methods
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- CRISPR and Genetic Engineering
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Hippo pathway signaling and YAP/TAZ
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Biochemical and Molecular Research
- HER2/EGFR in Cancer Research
- Endoplasmic Reticulum Stress and Disease
- Protein Kinase Regulation and GTPase Signaling
- Lung Cancer Treatments and Mutations
- Cytomegalovirus and herpesvirus research
- Calcium signaling and nucleotide metabolism
NYU Langone Health
2023-2025
Abstract Non–small lung cancers (NSCLC) frequently (∼30%) harbor KRAS driver mutations, half of which are KRASG12C. KRAS-mutant NSCLC with comutated STK11 and/or KEAP1 is particularly refractory to conventional, targeted, and immune therapy. Development KRASG12C inhibitors (G12Ci) provided a major therapeutic advance, but resistance still limits their efficacy. To identify genes whose deletion augments efficacy the G12Cis adagrasib (MRTX-849) or plus TNO155 (SHP2i), we performed genome-wide...
Introduction: Osimertinib, a covalent third-generation EGFR tyrosine kinase inhibitor (TKI) is the first-line standard of care for L858R and ex19del lung adenocarcinoma; however, tumors frequently acquire resistance through second-site mutations. Fourth-generation inhibitors designed to overcome common liabilities are in clinical development. Methods: We performed deep mutational scanning (DMS) domain context an driver mutation by transducing Ba/F3 cells with saturation library ~17,000...
Abstract Introduction: CDK4/6 inhibitors (CDK4/6i), such as palbociclib, combined with endocrine therapy, are first line therapies for advanced breast cancer (BrCa). CDK46i well tolerated but not curative and patients often experience resistance. Several studies have suggested molecular features of resistance to CDK4/6i. However, they based on small cohorts thus limit the ability define precision medicine opportunities resistant patients. Results: We assembled analyzed a multi-modal...
<p>Supplementary Figures 1-7 including Figure legends</p>
<p>Supplementary Figure Legends</p>
<p>Supplementary Figures 1-7 including Figure legends</p>
<p>Supplementary Figure Legends</p>